natgillin/translations-raw huggingface dataset:
The use of Elonva in combination with a GnRH agonist (another medicine to prevent your ovary from releasing an egg too early) is not recommended.
Ne preporučuje se primjena lijeka Elonva u kombinaciji s agonistom GnRH (drugim lijekom koji sprječava prerano oslobađanje jajne stanice iz jajnika).
The use of Emtricitabine/Tenofovir disoproxil Zentiva is not recommended in patients with severe renal impairment (creatinine clearance < 30 ml/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Emtricitabine/Tenofovir disoproxil Zentiva ne preporučuje se za bolesnike s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) i bolesnike kojima je potrebna hemodijaliza jer se kombiniranom tabletom ne mogu postići odgovarajuća smanjenja doze (vidjeti dijelove 4.2 i 5.2).
The use of enoxaparin for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied.
Primjena enoksaparina u tromboprofilaksi u trudnica s mehaničkim protezama srčanih zalistaka nije odgovarajuće ispitana.
The use of Epoetin alfa HEXAL in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Primjena Epoetina alfa HEXAL u bolesnika u kojih se planira veliki elektivni ortopedski kirurški zahvat i koji ne sudjeluju u programu autologne predonacije krvi je kontraindicirana ako imaju tešku bolest koronarnih arterija, perifernih arterija, karotida ili cerebralnu vaskularnu bolest, uključujući bolesnike s nedavnim infarktom miokarda ili cerebrovaskularnim incidentom.
The use of epoetin alfa is not recommended in lactating surgical patients participating in an autologous blood predonation programme.
Primjena epoetina alfa se ne preporučuje u kirurških bolesnica koje doje i sudjeluju u programu predonacije autologne krvi.
The use of epoetin theta in nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible accelerated progression of renal failure cannot be ruled out with certainty.
Uporabu epoetina theta kod nefrosklerotičnih bolesnika koji još nisu na dijalizi treba definirati individualno, jer se ne može sa sigurnošću isključiti moguća ubrzana progresija zatajenja bubrega.
The use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events including pulmonary embolism, acute myocardial infarction, cerebrovascular accident, and deep vein thrombosis.
Primjena lijekova koji stimuliraju eritropoezu bila je povezana s povećanim rizikom od tromboembolijskih događaja, uključujući plućnu emboliju, akutni infarkt miokarda, cerebrovaskularni incident i duboku vensku trombozu.
The use of Eucreas in children and adolescents up to 18 years of age is not recommended.
Eucreas se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
The use of EVARREST has not been studied in the following procedures, and there is therefore no information to show that it would be effective:
Primjena lijeka EVARREST nije ispitivana u sljedećim postupcima te stoga nema informacija koje bi potvrdile njegovu učinkovitost:
The use of EVICEL has not been studied in the following procedures, and there is therefore no information to show that it would be effective in these procedures:
Primjena lijeka EVICEL nije ispitana u sljedećim postupcima te stoga nema podataka koji bi ukazivali na njegovu djelotvornost kod sljedećih postupaka:
The use of Eviplera must be accompanied by the use of effective contraception (see section 4.5).
Uz primjenu lijeka Eviplera mora se koristiti učinkovita kontracepcija (vidjeti dio 4.5).
The use of EVOTAZ may be considered during pregnancy only if the potential benefit justifies the potential risk.
Primjena lijeka EVOTAZ može se razmatrati tijekom trudnoće samo ako moguća korist opravdava mogući rizik.
The use of Exforge in children and adolescents is not recommended (aged below 18 years old).
Primjena Exforgea u djece i adolescenata se ne preporučuje (ispod 18 godina starosti).
The use of Eylea in children or adolescents under 18 has not been studied because wet AMD, CRVO, BRVO, DME and myopic CNV occur mainly in adults.
Primjena lijeka Eylea u djece i adolescenata mlađih od 18 godina nije ispitana, zato što vlažni AMD, CRVO, BRVO, DME i miopijski CNV nastaju uglavnom u odraslih osoba.
The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the ULN according to the local reference range.
Primjena fibrinolitika u liječenju akutnog ishemijskog moždanog udara može se razmotriti u slučaju kada se bolesnik prijavi s dTV, ECT ili aPTV koje ne prelaze gornju granicu normale prema referentnom lokalnom rasponu.
The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the ULN according to the local reference range.
Primjena fibrinolitika u liječenju akutnog ishemijskog moždanog udara se razmatra ako dTV, ECT, ili aPTV bolesnika ne prelaze GGN, prema referentnom nacionalnom rasponu.
The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Pokazalo se da primjena filgrastimom mobiliziranih progenitorskih stanica preteča periferne krvi smanjuje jačinu i trajanje trombocitopenije nakon mijelosupresivne ili mijeloablativne kemoterapije.
The use of Galvus in children and adolescents up to 18 years of age is not recommended.
Galvus se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
The use of Gardasil 9 should be in accordance with official recommendations.
Gardasil 9 treba primijeniti sukladno službenim preporukama.
The use of Genvoya in children aged 11 years or under has not yet been studied.
Primjena lijeka Genvoya u djece u dobi od 11 godina i mlađoj još nije ispitana.
The use of gloves and aseptic technique is required.
Potrebno je koristiti rukavice i primijeniti aseptičku metodu.
The use of gloves and protective clothing is recommended.
Preporučuje se uporaba rukavica i zaštitne odjeće.
The use of gloves is required.
Obvezatno je korištenje rukavica.
The use of gloves, goggles and protective clothing when handling or administering ONIVYDE is recommended.
Pri rukovanju i primjeni lijeka ONIVYDE preporučuje se uporaba rukavica, naočala i zaštitne odjeće.
The use of glucose oxidase methods may give false negative results for glycosuria.
Primjena metoda s glukoza- oksidazom može dati lažno negativne rezultate za glikozuriju.
The use of haemodialysis and other forms of extracorporeal medicinal product removal have not been studied in sodium oxybate overdose.
Primjena hemodijalize i drugih oblika uklanjanja lijekova iz tijela nije ispitivano u slučajevima predoziranja natrijevim okibatom.
The use of high purity factor IX is rarely associated with such side effects.
Korištenje pripravaka visoke čistoće faktora IX je rijetko povezano s navedenim nuspojavama.
The use of Humira in pregnant women is not recommended.
Primjena lijeka Humira se ne preporučuje kod trudnica.
The use of Icandra in children and adolescents up to 18 years of age is not recommended.
Icandra se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
The use of INCIVO in combination with peginterferon alfa-2b
Primjena INCIVA u kombinaciji s peginterferonom alfa-2b
The use of Incurin is contraindicated during pregnancy, lactation and in animals younger than 1 year.
Korištenje Incurina je kontraindicirano tijekom graviditeta, laktacije i kod životinja mlađih od 1 godine.
The use of inhaled hypertonic saline was not permitted.
Primjena hipertonične otopine natrijevog klorida za inhalaciju nije bila dopuštena.
The use of interferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section “Do not use IntronA”). if you have cirrhosis or other liver problems (other than hepatitis B or C). if you have psoriasis, it may get worse during treatment with IntronA. when receiving IntronA, you may temporarily have a greater risk of getting an infection.
Primjena interferona alfa-2b kontraindicirana je u djece i adolescenata koji boluju ili su bolovali od teških psihijatrijskih bolesti (vidjeti dio "Nemojte primjenjivati IntronA"). ako imate cirozu ili druge tegobe s jetrom (osim hepatitisa B ili C). ako imate psorijazu, bolest se može pogoršati tijekom liječenja lijekom IntronA. dok uzimate IntronA možete privremeno imati povećan rizik od razvoja infekcije.
The use of ivacaftor in patients with severe hepatic impairment is therefore not recommended unless the benefits outweigh the risks.
U bolesnika s teškim oštećenjem funkcije jetre ne preporučuje se primjena ivakaftora, osim ako je korist od liječenja veća od rizika.
The use of Jalra in children and adolescents up to 18 years of age is not recommended.
Jalra se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
The use of Kentera in patients with hepatic impairment should be carefully monitored since oxybutynin is extensively hepatic metabolised.
Primjenu Kentere u bolesnika s jetrenim bolestima potrebno je pažljivo pratiti zato što se oksibutinin opsežno metabolizira u jetri.
The use of Kentera in patients with hepatic impairment should be carefully monitored.
Primjena Kentere u bolesnika s jetrenim oštećenjem treba biti pažljivo praćena.
The use of Kineret with tumour necrosis factor (TNF) antagonists (other medicines used in rheumatoid arthritis) is not recommended.
Ne preporuča se primjena lijeka Kineret s antagonistima čimbenika nekroze tumora (TNF) (drugi lijekovi koji se koriste u slučaju reumatoidnog artritisa).
The use of Kinzalmono in children and adolescents up to the age of 18 years is not recommended.
Primjena Kinzalmonoa u djece i adolescenata do dobi od 18 godina se ne preporučuje.
The use of LAVENTAIR has not been studied in patients with severe hepatic impairment and should be used with caution.
Primjena lijeka LAVENTAIR nije ispitivana u bolesnika s teškim oštećenjem jetrene funkcije pa se mora primjenjivati uz oprez.
The use of leflunomide with antimalarials used in rheumatic diseases (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive agents including T umour Necrosis Factor alpha-Inhibitors has not been adequately studied up to nowin randomised trials (with the exception of methotrexate, see section 4.5).
Do sada u randomiziranim ispitivanjima nije na odgovarajući način ispitivana primjena leflunomida s antimalaricima koji se koriste za reumatske bolesti (npr. klorokin i hidroksiklorokin), intramuskularno ili peroralno primijenjenim solima zlata, D-penicilaminom, azatioprinom te ostalim imunosupresivnim lijekovima uključujući inhibitore faktora nekroze tumora alfa (s izuzetkom metotreksata, vidjeti dio 4.5.).
The use of leflunomide with antimalarials used in rheumatic diseases (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive agents including Tumour Necrosis Factor alpha-Inhibitors has not been adequately studied up to nowin randomised trials (with the exception of methotrexate, see section 4.5).
Do sada u randomiziranim ispitivanjima nije na odgovarajući način ispitivana primjena leflunomida s antimalaricima koji se koriste za reumatske bolesti (npr. klorokin i hidroksiklorokin), intramuskularno ili peroralno primijenjenim solima zlata, D-penicilaminom, azatioprinom te ostalim imunosupresivnim lijekovima uključujući inhibitore faktora nekroze tumora alfa (s izuzetkom metotreksata, vidjeti dio 4.5.).
The use of LITAK in children has not been investigated (see section 4.2).
Primjena lijeka LITAK u djece nije ispitivana (vidjeti dio 4.2).
The use of live vaccines should be avoided during treatment with Afinitor (see section 4.5).
Tijekom liječenja Afinitorom mora se izbjegavati primjena živih cjepiva (vidjeti dio 4.5).
The use of live vaccines should be avoided during treatment with Rapamune.
Mora se izbjegavati primjenu živih cjepiva tijekom liječenja Rapamuneom.
The use of live vaccines should be avoided during treatment with Torisel.
Primjenu živih cjepiva treba izbjegavati tijekom liječenja Toriselom.
The use of low purity factor IX products has been associated with instances of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism.
Primjena pripravaka niske čistoće faktora IX povezana je s pojavom infarkta miokarda, diseminiranom intravaskularnom koagulacijom, venskom trombozom i plućnom embolijom.
The use of Lucentis in children and adolescents has not been studied and is therefore not recommended.
Primjena Lucentisa u djece i adolescenata nije ispitana te se stoga ne preporučuje.
The use of Lutetium (177Lu)-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Lijekovi radioaktivno označeni lutecijem (177Lu) kontraindicirani su u slučaju ustanovljene trudnoće, kada se sumnja na trudnoću ili kada trudnoća nije isključena (vidjeti dio 4.3).
The use of medicinal products called amantadine (for the treatment of Parkinson’s disease),
Trebalo bi izbjegavati istodobnu primjenu lijekova koji se zovu amantadin (za liječenje Parkinsonove bolesti)
The use of medicinal products called amantadine (for the treatment of Parkinson’s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.
Trebalo bi izbjegavati istodobnu primjenu lijekova koji se zovu amantadin (za liječenje Parkinsonove bolesti), ketamin (tvar koja se obično koristi kao anestetik), dekstrometorfan (obično se koristi za liječenje kašlja) i ostalih antagonista NMDA.
The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.
Primjena lijekova koji utječu na sustav renin-angiotenzin-aldosteron može izazvati hiperkalemiju.
The use of memantine in pregnant women is not recommended.
Primjena memantina u trudnica se ne preporučuje.
The use of memantine in pregnant women is not recommended.
Trudnoća: trudnicama se ne preporučuje upotreba memantina.
The use of Metalyse in children and adolescents up to the age of 18 years is not recommended.
Primjena Metalysea kod djece i adolescenata do dobi od 18 godina se ne preporučuje.
The use of Metalyse in children and adolescents up to the age old 18 years is not recommended.
Primjena Metalysea kod djece i adolescenata do dobi od 18 godina se ne preporučuje.
The use of Micardis in children and adolescents up to the age of 18 years is not recommended.
Primjena Micardisa u djece i adolescenata do dobi od 18 godina se ne preporučuje.
The use of mifamurtide concurrently with ciclosporin or other calcineurin inhibitors is contraindicated due to their hypothesised effect on splenic macrophages and mononuclear phagocytic function (see section 4.3).
Istovremena primjena mifamurtida sa ciklosporinom ili drugim inhibitorima kalcineurina je kontraindicirana zbog njihovog pretpostavljenog utjecaja na funkciju makrofaga i mononuklearnih fagocita u slezeni (vidjeti dio 4.3).
The use of Moventig during pregnancy is not recommended.
Ne preporučuje se primjena lijeka Moventig u trudnoći.
The use of Myocet should be confined to units specialised in the administration of cytotoxic chemotherapy and should only be administered under the supervision of a physician experienced in the use of chemotherapy.
Primjenu Myoceta treba ograničiti na odjele koji su specijalizirani u primjeni citotoksičnih lijekova te ih treba primjenjivati samo pod nadzorom liječnika iskusnog u primjeni kemoterapije.
The use of naloxegol in the paediatric population has not been studied.
Primjena naloksegola u pedijatrijskoj populaciji nije ispitivana.
The use of NEVANAC is not recommended during pregnancy.
Primjena NEVANAC-a ne preporučuje se tijekom trudnoće.
The use of Nonafact may also produce an increase in body temperature in rare cases.
Korištenje lijeka Nonafact u rijetkim slučajevima može dovesti do porasta tjelesne temperature.
The use of Norvir may be considered in pregnancy only when the benefits outweigh the risk to the foetus.
Primjena lijeka Norvir u trudnoći smije se razmotriti samo ako očekivana korist nadmašuje rizik za plod.
The use of NovoThirteen may be necessary during pregnancy and breast-feeding.
Primjena lijeka NovoThirteen će možda biti neophodna tijekom trudnoće i dojenja.
The use of NULOJIX is not recommended if you have had a liver transplant.
Ne preporučuje se primjena lijeka NULOJIX nakon presađivanja jetre.
The use of Odefsey should be accompanied by the use of effective contraception (see section 4.5).
Uz primjenu lijeka Odefsey mora se koristiti učinkovita kontracepcija (vidjeti dijelove 4.5).
The use of oestrogen-only HRT has been associated with a slightly increased risk of ovarian cancer.
Uporaba hormonske nadomjesne terapije (HNT) koja sadrži samo estrogen povezaje se s blago povećanim rizikom od nastanka raka jajnika.
The use of Olanzapine Apotex in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena Olanzapine Apotexa u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of OLANZAPINE CIPLA in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena lijeka OLANZAPINE CIPLA u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Olanzapine Glenmark Europe in elderly patients with dememtia is not recommended as it may have serious side effects.
Primjena lijeka Olanzapin Glenmark Europe u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Olanzapine Glenmark in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena lijeka Olanzapin Glenmark u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Olanzapine Mylan in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena Olanzapine Mylan u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Olanzapine Teva in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena Olanzapina Teva u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Olazax Disperzi in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena lijeka Olazax Disperzi u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of OLAZAX in elderly patients with dementia is not recommended as it may have serious side effects.
Primjena lijeka Olazax u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
The use of Omidria during intraocular lens replacement surgery may cause vision to be temporarily affected. (see section 4.7).
Primjena lijeka Omidria tijekom kirurškog zahvata zamjene intraokularne leće može privremeno utjecati na vid. (vidjeti dio 4.7).
The use of Oncaspar can lead to fluctuating coagulation factors.
Primjena Oncaspara može dovesti do fluktuacije faktora koagulacije.
The use of Onduarp in children and adolescents up to the age of 18 years is not recommended.
Primjena Onduarpa kod djece i adolescenata do 18 godina starosti se ne preporučuje.
The use of ONIVYDE in patients with significant renal impairment has not been established (see section 5.2).
Primjena lijeka ONIVYDE u bolesnika sa značajnim oštećenjem bubrega nije ustanovljena (vidjeti dio 5.2).
The use of ONIVYDE should be avoided in patients with bilirubin > 2.0 mg/dl, or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 times upper limit of normal (ULN) or > 5 times ULN if liver metastasis is present (see section 4.4).
Primjenu lijeka ONIVYDE treba izbjegavati u bolesnika s razinom bilirubina > 2,0 mg/dl ili vrijednostima aspartat aminotransferaze (AST) i alanin aminotransferaze (ALT) > 2,5 puta iznad gornje granice normale (GGN) ili > 5 puta GGN ako su prisutne metastaze u jetri (vidjeti dio 4.4).
The use of oral corticosteroids should be considered in those instances in which anti-pyretics are insufficient.
Potrebno je razmotriti primjenu oralnih kortikosteroida u slučajevima u kojima su antipiretici nedovoljni.
The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes to renal failure.
Primjena orlistata može biti povezana s hiperoksalurijom i nefropatijom uzrokovanom oksalatima, koje ponekad mogu dovesti do zatajenja bubrega.
The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made.
Prilikom primjene drugih depresiva središnjeg živčanog sustava očekuje se potenciranje učinaka deksmedetomidina, stoga je potrebno prilagoditi dozu.
The use of Pegasys and ribavirin combination therapy in chronic hepatitis C patients who failed prior treatment has not been adequately studied in patients who discontinued prior therapy for haematological adverse reactions.
Primjena kombiniranog liječenja lijekom Pegasys i ribavirinom u bolesnika s kroničnim hepatitisom C koji nisu odgovorili na ranije liječenje nije dovoljno ispitana u bolesnika koji su prekinuli prethodno liječenje zbog hematoloških nuspojava.
The use of Pegasys in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).
Primjena lijeka Pegasys u djece i adolescenata s postojećim ili ranijim teškim psihijatrijskim bolestima je kontraindicirana (vidjeti dio 4.3).
The use of pneumococcal conjugate vaccine does not replace the use of
Primjena pneumokoknog konjugiranog cjepiva ne može zamijeniti primjenu
The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccines in children  24 months of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness or who are immunocompromised) placing them at higher risk for invasive disease due to Streptococcus pneumoniae.
Primjena konjugiranog pneumokoknog cjepiva ne može zamijeniti primjenu 23-valentnog pneumokoknog polisaharidnog cjepiva u djece u dobi ≥ 24 mjeseci koja imaju neku bolest (kao što je anemija srpastih stanica, asplenija, HIV-infekcija, kronična bolest ili su imunokompromitirana), zbog koje su izložena većem riziku od invazivne bolesti prouzročene bakterijom Streptococcus pneumoniae.
The use of Pritor in children and adolescents up to the age of 18 years is not recommended.
Primjena Pritora u djece i adolescenata do dobi od 18 godina se ne preporučuje.
The use of PritorPlus during breast feeding is not recommended.
Primjena PritorPlusa tijekom dojenja se ne preporučuje.
The use of PritorPlus in children and adolescents up to the age of 18 years is not recommended.
Primjena PritorPlusa kod djece i adolescenata ispod 18 godina starosti se ne preporučuje.
The use of Prolia in children and adolescents has not been studied.
Korištenje lijeka Prolia u djece i adolescenata nije bilo ispitivano.